KRAS and neoplasm: Similarly, the co-existence of KRAS and EGFR mutations in the same tumor tissue could be interpreted as either double mutation in the crizotinib-resistant tumor cells or more likely as the occurrence of two different tumor subpopulations with constitutive activation of either the EGFR or the KRAS signaling pathway as different mechanisms of acquired crizotinib-resistance.